Aarey Drugs & Pharmaceuticals (BOM:524412) Beneish M-Score: -2.92 (As of Jul. 01, 2026)


BOM:524412 Aarey Drugs & Pharmaceuticals Ltd BOM:524412
60 GF Score
Price ₹89.67
GF Value ₹58.28
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Aarey Drugs & Pharmaceuticals Beneish M-Score?

Aarey Drugs & Pharmaceuticals BOM:524412 -2.00% 60 Beneish M-Score is -2.92 as of Jul. 01, 2026. GuruFocus rates BOM:524412 with a GF Score™ of 60/100 and a GF Value™ of ₹58.28 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 909 Drug Manufacturers companies, Aarey Drugs & Pharmaceuticals ranks better than 80.53% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.92 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Aarey Drugs & Pharmaceuticals's Beneish M-Score or its related term are showing as below:

BOM:524412' s Beneish M-Score Range Over the Past 10 Years
Min: -3.02   Med: -2.21   Max: 8.37
Current: -2.92

During the past 13 years, the highest Beneish M-Score of Aarey Drugs & Pharmaceuticals was 8.37. The lowest was -3.02. And the median was -2.21.


Aarey Drugs & Pharmaceuticals Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Aarey Drugs & Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aarey Drugs & Pharmaceuticals Beneish M-Score Chart

Aarey Drugs & Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.37 -1.63 -2.46 -3.02 -2.92

Aarey Drugs & Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.02 0.00 0.00 0.00 -2.92

BOM:524412 vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aarey Drugs & Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aarey Drugs & Pharmaceuticals Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aarey Drugs & Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Aarey Drugs & Pharmaceuticals's Beneish M-Score falls into.


BOM:524412
60GF Score
Aarey Drugs & Pharmaceuticals Ltd BOM:524412
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aarey Drugs & Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Aarey Drugs & Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9228+0.528 * 0.6666+0.404 * 0.8865+0.892 * 0.9965+0.115 * 1.1143
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.4619+4.679 * -0.020763-0.327 * 0.9444
=-2.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹1,503 Mil.
Revenue was ₹4,723 Mil.
Gross Profit was ₹178 Mil.
Total Current Assets was ₹2,629 Mil.
Total Assets was ₹2,972 Mil.
Property, Plant and Equipment(Net PPE) was ₹258 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹29 Mil.
Selling, General, & Admin. Expense(SGA) was ₹49 Mil.
Total Current Liabilities was ₹1,451 Mil.
Long-Term Debt & Capital Lease Obligation was ₹10 Mil.
Net Income was ₹40 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹101 Mil.
Total Receivables was ₹1,634 Mil.
Revenue was ₹4,739 Mil.
Gross Profit was ₹119 Mil.
Total Current Assets was ₹2,656 Mil.
Total Assets was ₹2,906 Mil.
Property, Plant and Equipment(Net PPE) was ₹156 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹19 Mil.
Selling, General, & Admin. Expense(SGA) was ₹34 Mil.
Total Current Liabilities was ₹1,492 Mil.
Long-Term Debt & Capital Lease Obligation was ₹20 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1502.592 / 4722.69) / (1634.023 / 4739.433)
=0.318164 / 0.344772
=0.9228

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(118.821 / 4739.433) / (177.62 / 4722.69)
=0.025071 / 0.03761
=0.6666

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2629.422 + 257.784) / 2972.467) / (1 - (2656.19 + 155.706) / 2905.92)
=0.028684 / 0.032356
=0.8865

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=4722.69 / 4739.433
=0.9965

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(19.449 / (19.449 + 155.706)) / (28.53 / (28.53 + 257.784))
=0.111039 / 0.099646
=1.1143

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(49.027 / 4722.69) / (33.657 / 4739.433)
=0.010381 / 0.007101
=1.4619

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((9.74 + 1450.766) / 2972.467) / ((19.866 + 1492.061) / 2905.92)
=0.491345 / 0.520292
=0.9444

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(39.676 - 0 - 101.392) / 2972.467
=-0.020763

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Aarey Drugs & Pharmaceuticals has a M-score of -2.92 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.92 mean?
Aarey Drugs & Pharmaceuticals (BOM:524412) has a Beneish M-Score of -2.92 as of Jul. 01, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Aarey Drugs & Pharmaceuticals and its competitors. According to the industry distribution chart, Aarey Drugs & Pharmaceuticals ranks #177 out of 909 companies in the Drug Manufacturers industry, placing it in the top 19.5%.
Is Aarey Drugs & Pharmaceuticals' Beneish M-Score too high?
Aarey Drugs & Pharmaceuticals' current Beneish M-Score is -2.92. Based on the distribution chart, Aarey Drugs & Pharmaceuticals ranks #177 out of 909 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Aarey Drugs & Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aarey Drugs & Pharmaceuticals' Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aarey Drugs & Pharmaceuticals ranks #177 out of 909 companies for Beneish M-Score. This places Aarey Drugs & Pharmaceuticals in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Aarey Drugs & Pharmaceuticals and its competitors. Aarey Drugs & Pharmaceuticals's current Beneish M-Score is -2.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarey Drugs & Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aarey Drugs & Pharmaceuticals (BOM:524412) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹58.28, compared to a current price of ₹89.67 — trading 53.9% above its estimated fair value. The current Beneish M-Score is -2.92. Aarey Drugs & Pharmaceuticals' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Aarey Drugs & Pharmaceuticals (BOM:524412), the current Beneish M-Score is -2.92 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aarey Drugs & Pharmaceuticals (BOM:524412) Overvalued in 2026?

Based on GuruFocus' analysis, Aarey Drugs & Pharmaceuticals stock appears to be overvalued. The current stock price of ₹89.67 is trading 53.9% above its estimated GF Value™ of ₹58.28. GuruFocus considers Aarey Drugs & Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BOM:524412:

  • Beneish M-Score: -2.92
  • GF Value™: ₹58.28 vs. price of ₹89.67 (53.9% above fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the BOM:524412 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aarey Drugs & Pharmaceuticals Business Description

Other Exchanges AAREYDRUGS:India
Address 340/348, Narshi Natha Street, 107, Sahakar Bhavan, Masjid Bunder, Mumbai, MH, IND, 400 009
Aarey Drugs & Pharmaceuticals Ltd is engaged in bulk drug manufacturing and offers products for industrial applications. The company manufactures active pharmaceutical ingredients, intermediates, and specialty chemicals. It is also involved in the trading of industrial solvents and chemicals. The products offered by the company include N-Methyl urea, Dimethyl urea, Mefenamic acid, Metformin, Doxaphylline, and BMD among others. The company principally carries out its business operations in India.
60GF Score

Get the complete analysis for BOM:524412

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹89.67
Price
₹58.28
GF Value